US 11,697,686 B2
Anti-PD-L1 antibody for detecting PD-L1
Satoru Konnai, Hokkaido (JP); Kazuhiko Ohashi, Hokkaido (JP); Shiro Murata, Hokkaido (JP); Tomohiro Okagawa, Hokkaido (JP); Asami Nishimori, Hokkaido (JP); Naoya Maekawa, Hokkaido (JP); Satoshi Takagi, Hokkaido (JP); Yumiko Kagawa, Hokkaido (JP); Yasuhiko Suzuki, Hokkaido (JP); and Chie Nakajima, Hokkaido (JP)
Assigned to NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, Hokkaido (JP); and FUSO PHARMACEUTICAL INDUSTRIES, LTD., Osaka (JP)
Filed by National University Corporation Hokkaido University, Hokkaido (JP); and Fuso Pharmaceutical Industries, Ltd., Osaka (JP)
Filed on Oct. 28, 2020, as Appl. No. 16/949,415.
Application 16/949,415 is a continuation of application No. 16/491,145, granted, now 10,865,246, previously published as PCT/JP2018/011895, filed on Mar. 23, 2018.
Claims priority of application No. 2017-061389 (JP), filed on Mar. 27, 2017.
Prior Publication US 2021/0079095 A1, Mar. 18, 2021
Int. Cl. C07K 16/28 (2006.01); C12N 15/85 (2006.01); G01N 33/569 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/2827 (2013.01) [C12N 15/85 (2013.01); G01N 33/5695 (2013.01); G01N 33/57492 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); G01N 2800/26 (2013.01)] 13 Claims
 
1. A method to diagnose cancer and/or infection comprising contacting in vitro one or more cells from a subject with an antibody; and
determining if said antibody binds to said one or more cells,
wherein increased binding to said cells as compared to a control is indicative of cancer and/or infection,
wherein the cancer is a cancer where cancer cells express PD-L1,
wherein the infection is an infection where infected cells express PD-L1, and
wherein said antibody is an anti-PD-L1 antibody comprising
(a) a light chain comprising CDR1 having the amino acid sequence of KSISKY (SEQ ID NO: 1), CDR2 having the amino acid sequence of SGS and CDR3 having the amino acid sequence of QQHNEYPLT (SEQ ID NO: 2) and
(b) a heavy chain comprising CDR1 having the amino acid sequence of GYTFTDYI (SEQ ID NO: 3), CDR2 having the amino acid sequence of INPDSGGN (SEQ ID NO: 4) and CDR3 having the amino acid sequence of ARGITMMVVISHWKFDF (SEQ ID NO: 5),
wherein said antibody binds ovine, bovine, porcine or canine PD-L1 proteins, and
wherein the cancer is not malignant melanoma.